These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 20826913)

  • 1. Peptides in low molecular weight fraction of serum associated with hepatocellular carcinoma.
    An Y; Bekesova S; Edwards N; Goldman R
    Dis Markers; 2010; 29(1):11-20. PubMed ID: 20826913
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enrichment of low molecular weight fraction of serum for MS analysis of peptides associated with hepatocellular carcinoma.
    Orvisky E; Drake SK; Martin BM; Abdel-Hamid M; Ressom HW; Varghese RS; An Y; Saha D; Hortin GL; Loffredo CA; Goldman R
    Proteomics; 2006 May; 6(9):2895-902. PubMed ID: 16586431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of MALDI-TOF mass spectrometry data for discovery of peptide and glycan biomarkers of hepatocellular carcinoma.
    Ressom HW; Varghese RS; Goldman L; An Y; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Drake SK; Goldman R
    J Proteome Res; 2008 Feb; 7(2):603-10. PubMed ID: 18189345
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum.
    Goldman R; Ressom HW; Abdel-Hamid M; Goldman L; Wang A; Varghese RS; An Y; Loffredo CA; Drake SK; Eissa SA; Gouda I; Ezzat S; Moiseiwitsch FS
    Carcinogenesis; 2007 Oct; 28(10):2149-53. PubMed ID: 17724376
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mass spectrometry-based serum peptide profiling in hepatocellular carcinoma with bone metastasis.
    He J; Zeng ZC; Xiang ZL; Yang P
    World J Gastroenterol; 2014 Mar; 20(11):3025-32. PubMed ID: 24659894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum peptidome patterns of hepatocellular carcinoma based on magnetic bead separation and mass spectrometry analysis.
    Ying X; Han SX; Wang JL; Zhou X; Jin GH; Jin L; Wang H; Wu L; Zhang J; Zhu Q
    Diagn Pathol; 2013 Aug; 8():130. PubMed ID: 23915185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LC-MS based serum metabolomics for identification of hepatocellular carcinoma biomarkers in Egyptian cohort.
    Xiao JF; Varghese RS; Zhou B; Nezami Ranjbar MR; Zhao Y; Tsai TH; Di Poto C; Wang J; Goerlitz D; Luo Y; Cheema AK; Sarhan N; Soliman H; Tadesse MG; Ziada DH; Ressom HW
    J Proteome Res; 2012 Dec; 11(12):5914-23. PubMed ID: 23078175
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases.
    Paradis V; Degos F; Dargère D; Pham N; Belghiti J; Degott C; Janeau JL; Bezeaud A; Delforge D; Cubizolles M; Laurendeau I; Bedossa P
    Hepatology; 2005 Jan; 41(1):40-7. PubMed ID: 15690480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ITIH4: Effective Serum Marker, Early Warning and Diagnosis, Hepatocellular Carcinoma.
    Li X; Li B; Li B; Guo T; Sun Z; Li X; Chen L; Chen W; Chen P; Mao Y; Zeng Y
    Pathol Oncol Res; 2018 Jul; 24(3):663-670. PubMed ID: 28828637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced detection of early hepatocellular carcinoma by serum SELDI-TOF proteomic signature combined with alpha-fetoprotein marker.
    Chen L; Ho DW; Lee NP; Sun S; Lam B; Wong KF; Yi X; Lau GK; Ng EW; Poon TC; Lai PB; Cai Z; Peng J; Leng X; Poon RT; Luk JM
    Ann Surg Oncol; 2010 Sep; 17(9):2518-25. PubMed ID: 20354800
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased concentrations of apo A-I and apo A-II fragments in the serum of patients with hepatocellular carcinoma by magnetic beads-assisted MALDI-TOF mass spectrometry.
    Liu Y; Sogawa K; Sunaga M; Umemura H; Satoh M; Kazami T; Yoshikawa M; Tomonaga T; Yokosuka O; Nomura F
    Am J Clin Pathol; 2014 Jan; 141(1):52-61. PubMed ID: 24343737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of hepatocellular carcinoma using glycomic analysis.
    Goldman R; Ressom HW; Varghese RS; Goldman L; Bascug G; Loffredo CA; Abdel-Hamid M; Gouda I; Ezzat S; Kyselova Z; Mechref Y; Novotny MV
    Clin Cancer Res; 2009 Mar; 15(5):1808-13. PubMed ID: 19223512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proteomic profiling of hepatitis B virus-related hepatocellular carcinoma with magnetic bead-based matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
    Liu T; Xue R; Huang X; Zhang D; Dong L; Wu H; Shen X
    Acta Biochim Biophys Sin (Shanghai); 2011 Jul; 43(7):542-50. PubMed ID: 21659380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying serum biomarkers for TACE therapy efficiency of hepatocellular carcinoma.
    Li CY; Wang XL; Wang JH; Yan ZP; Gong GQ; Cheng JM; Chen Y; Liu LX; Li GP; Wang CG; Shi DH
    Front Biosci (Elite Ed); 2011 Jan; 3(1):212-20. PubMed ID: 21196300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integrated peptide and glycan biomarker discovery using MALDI-TOF mass spectrometry.
    Varghese RS; Goldman L; An Y; Loffredo CA; Abdel-Hamid M; Kyselova Z; Mechref Y; Novotny M; Drake SK; Goldman R; Ressom HW
    Annu Int Conf IEEE Eng Med Biol Soc; 2008; 2008():3791-4. PubMed ID: 19163537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis.
    Feng JT; Liu YK; Song HY; Dai Z; Qin LX; Almofti MR; Fang CY; Lu HJ; Yang PY; Tang ZY
    Proteomics; 2005 Nov; 5(17):4581-8. PubMed ID: 16240287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of beta2-microgloblin as a candidate for early diagnosis of imaging-invisible hepatocellular carcinoma in patient with liver cirrhosis.
    Saito Y; Oba N; Nishinakagawa S; Mizuguchi Y; Kojima T; Nomura K; Nakatsura T
    Oncol Rep; 2010 May; 23(5):1325-30. PubMed ID: 20372847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identifying serological biomarkers of hepatocellular carcinoma using surface-enhanced laser desorption/ionization-time-of-flight mass spectroscopy.
    Wu FX; Wang Q; Zhang ZM; Huang S; Yuan WP; Liu JY; Ban KC; Zhao YN
    Cancer Lett; 2009 Jul; 279(2):163-70. PubMed ID: 19268439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NMR and LC/MS-based global metabolomics to identify serum biomarkers differentiating hepatocellular carcinoma from liver cirrhosis.
    Liu Y; Hong Z; Tan G; Dong X; Yang G; Zhao L; Chen X; Zhu Z; Lou Z; Qian B; Zhang G; Chai Y
    Int J Cancer; 2014 Aug; 135(3):658-68. PubMed ID: 24382646
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemically-assisted fragmentation combined with multi-dimensional liquid chromatography and matrix-assisted laser desorption/ionization post source decay, matrix-assisted laser desorption/ionization tandem time-of flight or matrix-assisted laser desorption/ionization tandem mass spectrometry for improved sequencing of tryptic peptides.
    Flensburg J; Tangen A; Prieto M; Hellman U; Wadensten H
    Eur J Mass Spectrom (Chichester); 2005; 11(2):169-79. PubMed ID: 16046801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.